Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine

Inclusion Criteria: * The participant has a diagnosis of CM as defined by IHS ICHD-3 guidelines confirmed at screening visit with a history of migraine onset at least 12 months prior to the Screening Visit. * The participant has a migraine onset at ≤50 years of age. * The participant has ≥8 migraine days per month for each month within the past 3 months prior to the Screening Visit. * The participant fulfils the following criteria for migraine in prospectively collected information in the eDiary during the screening period: * Migraine occurring on ≥8 days and headache occurring on ≥15 to ≤26 days. * The participant has demonstrated compliance with the Headache eDiary by entry of data for at least 24 of the 28 days following the Screening Visit. * The participant is aged ≥18 (≥20 for Taiwan) and ≤75 years at the Screening Visit. Exclusion Criteria: * The participant has received any medication targeting the calcitonin gene-related peptide (CGRP) pathway as preventive treatment of migraine. * The participant has confounding and clinically significant pain syndromes, (for example, fibromyalgia, chronic low back pain, complex regional pain syndrome). * The participant has a diagnosis of acute or active temporomandibular disorder. * The participant has a history or diagnosis of chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes such as hemiplegic migraine (sporadic and familial), oph…